How to buy Evogene stock - 07 March

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Evogene stock

Own Evogene stock in just a few minutes.

Fact checked

Evogene Ltd is a biotechnology business based in the US. Evogene shares (EVGN) are listed on the NASDAQ and all prices are listed in US Dollars. Evogene employs 143 staff and has a trailing 12-month revenue of around USD$805,000.

How to buy shares in Evogene

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Evogene. Find the stock by name or ticker symbol: EVGN. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Evogene reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Evogene, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Evogene. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Evogene share price

Use our graph to track the performance of EVGN stocks over time.

Evogene shares at a glance

Information last updated 2021-03-03.
52-week rangeUSD$0.75 - USD$10.24
50-day moving average USD$7.1079
200-day moving average USD$4.2348
Wall St. target priceUSD$15
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-0.715

Buy Evogene shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Robinhood
$0
Stocks, Options, ETFs, Gold/Commodities
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get two free stock valued between $2.50 and $250
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
TradeStation
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$50
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Tastyworks
$0
Stocks, Options, Cryptocurrency
Stocks & ETFs: $1/contract to open, $0 to close, $10 max/leg
Futures: $2.50/contract to open, $0 to close
0%
Get 100 shares of stock (worth $1 to $6 a share)
Open and fund a new cash or margin account with $2,000+
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
Interactive Brokers
$0
Stocks, Bonds, Options
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Evogene stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Evogene financials

Revenue TTM USD$805,000
Gross profit TTM USD$419,000
Return on assets TTM -21.52%
Return on equity TTM -39.5%
Profit margin 0%
Book value $1.42
Market capitalisation USD$222 million

TTM: trailing 12 months

Shorting Evogene shares

There are currently 1.4 million Evogene shares held short by investors – that's known as Evogene's "short interest". This figure is 16.5% down from 1.7 million last month.

There are a few different ways that this level of interest in shorting Evogene shares can be evaluated.

Evogene's "short interest ratio" (SIR)

Evogene's "short interest ratio" (SIR) is the quantity of Evogene shares currently shorted divided by the average quantity of Evogene shares traded daily (recently around 2.1 million). Evogene's SIR currently stands at 0.66. In other words for every 100,000 Evogene shares traded daily on the market, roughly 660 shares are currently held short.

However Evogene's short interest can also be evaluated against the total number of Evogene shares, or, against the total number of tradable Evogene shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Evogene's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Evogene shares in existence, roughly 40 shares are currently held short) or 0.0431% of the tradable shares (for every 100,000 tradable Evogene shares, roughly 43 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Evogene.

Find out more about how you can short Evogene stock.

Evogene share dividends

We're not expecting Evogene to pay a dividend over the next 12 months.

Have Evogene's shares ever split?

Evogene's shares were split on a 1:2 basis on 19 November 2013. So if you had owned 2 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Evogene shares – just the quantity. However, indirectly, the new 100% higher share price could have impacted the market appetite for Evogene shares which in turn could have impacted Evogene's share price.

Evogene share price volatility

Over the last 12 months, Evogene's shares have ranged in value from as little as $0.75 up to $10.24. A popular way to gauge a stock's volatility is its "beta".

EVGN.US volatility(beta: 0.53)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Evogene's is 0.5341. This would suggest that Evogene's shares are less volatile than average (for this exchange).

Evogene overview

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The CPB platform, incorporating a deep understanding of biology leveraged through big data and artificial intelligence, designed to computationally discover and uniquely guide the development of life-science products based on microbes, small molecules, and genetic elements. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Industrial Application segment develops enhanced castor bean seeds to serve as a feedstock source for biofuel and other industrial uses. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and multi drug resistant organisms. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer; and through its subsidiary, Canonic Ltd., has a collaboration agreement with Cannbit Ltd., a subsidiary of Tikun Olam-Cannbit Ltd. for the development of novel medical cannabis products. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site